Effectiveness of Treatment of Chronic Viral Hepatitis C by Direct-Acting Antivirals in Togo

• 作者: Aklesso Bagny Datouda Redah Laconi Kaaga Laté Mawuli Lawson-Ananissoh Lidaw Kogoe Oumboma Bouglouga Rafiou El-Hadji Yakoubou
• 来源期刊: 肠胃病学期刊(英文)
• 学科: 医学
• 关键词: VIRAL Hepatitis C Direct-Acting ANTIVIRALS SUSTAINED Virological Response TOGO
• 年，卷（期）: 2019,（7）
• 页码范围: 125-133
• 页数: 9页
• 分类号: R5

摘要

Background: Viral hepatitis C is the second leading cause of hepatocellular carcinoma after hepatitis B in Africa and Togo in particular. The advent of direct acting antivirals has revolutionized the care and prognosis of patients infected with hepatitis C virus (HCV). Objective: To evaluate the sustained virological response (SVR) 12 weeks after oral treatment without interferon in HCV infected patients with genotypes 1 and 2. Patients and Method: Descriptive and analytical study based on the retrospective collection of data in the hepatogastroenterology unit of the University Hospital Campus of Lome (Togo) from July 11, 2016 to April 22, 2018. All patients who had a chronic viral hepatitis C with viral replication, naive, regardless of the genotype, regardless of the degree of liver fibrosis, and who had completed their treatment with direct-acting antivirals were included. Results: We recruited 84 patients, 60 of whom were infected with HCV genotype 2 (71.43%) and 24 with HCV genotype 1 (28.57%). There were 58 men and 26 women (sex ratio: 0.45). In HCV genotype 1 patients, the median age was 54.29 years and Sofosbuvir/Ledipasvir was the most used combination (62.50%). In HCV genotype 2 patients, the median age was 54.5 years and Sofosbuvir associated with Ribavirin was the most used treatment (81.66%). The virological response at the end of treatment was 100% (genotype 1) and 93.30% (genotype 2). The SVR 12 was 100% (genotype 1) and 91.70% (genotype 2). Five patients were in treatment failure (genotype 2). Conclusion: Direct-acting antivirals were effective in our patients. The rate of sustained virological response was above 90%.